ARWR logo

ARWR
Arrowhead Pharmaceuticals Inc.

12,387
Mkt Cap
$10.24B
Volume
2.7M
52W High
$79.48
52W Low
$13.42
PE Ratio
-33.83
ARWR Fundamentals
Price
$72.69
Prev Close
$77.95
Open
$76.50
50D MA
$65.06
Beta
1.65
Avg. Volume
1.77M
EPS (Annual)
-$0.0122
P/B
16.64
Rev/Employee
$1.17M
$4,464.99
Loading...
Loading...
News
all
press releases
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
Zacks·2d ago
News Placeholder
Strs Ohio Has $2.09 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR
Strs Ohio grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 205.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·3d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 12-Month High - Time to Buy?
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High - Should You Buy...
MarketBeat·4d ago
News Placeholder
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...
Business Wire·4d ago
News Placeholder
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference May 12-14, 2026 Type...
Business Wire·5d ago
News Placeholder
Kornitzer Capital Management Inc. KS Makes New $2.38 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Kornitzer Capital Management Inc. KS bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent filing with...
MarketBeat·6d ago
News Placeholder
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. lowered its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent Form 13F...
MarketBeat·7d ago
News Placeholder
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Now Covered by JPMorgan Chase & Co.
JPMorgan Chase & Co. assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Friday. They set an "overweight" rating and a $88.00 price target on the stock...
MarketBeat·8d ago
News Placeholder
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine...
Business Wire·8d ago
<
1
2
...
>

Latest ARWR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.